The Therapeutic Potential of Targeting the CHD Protein Family in Cancer

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2024 Feb 17

PMID 38367868

Authors

Min Zhang

Kaiyuan Wu

Weijie Zhang

Xia Lin

Qi Cao

Lili Zhang

Kaifu Chen

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-of-function mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment.

References

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Fan J, Lou B, Chen W, Zhang J, Lin S, Lv F . Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol. 2014; 35(11):11523-32. DOI: 10.1007/s13277-014-2358-2. View

Wang Y, Chen Y, Bao L, Zhang B, Wang J, Kumar A . CHD4 Promotes Breast Cancer Progression as a Coactivator of Hypoxia-Inducible Factors. Cancer Res. 2020; 80(18):3880-3891. PMC: 7501193. DOI: 10.1158/0008-5472.CAN-20-1049. View

Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M . CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013; 73(9):2795-805. DOI: 10.1158/0008-5472.CAN-12-1342. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

Ding Y, Li N, Dong B, Guo W, Wei H, Chen Q . Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2018; 129(2):759-773. PMC: 6355211. DOI: 10.1172/JCI123557. View

Girdler F, Gascoigne K, Eyers P, Hartmuth S, Crafter C, Foote K . Validating Aurora B as an anti-cancer drug target. J Cell Sci. 2006; 119(Pt 17):3664-75. DOI: 10.1242/jcs.03145. View

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

10.

Nio K, Yamashita T, Okada H, Kondo M, Hayashi T, Hara Y . Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma. J Hepatol. 2015; 63(5):1164-72. DOI: 10.1016/j.jhep.2015.06.009. View

11.

Feinberg A, Koldobskiy M, Gondor A . Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016; 17(5):284-99. PMC: 4888057. DOI: 10.1038/nrg.2016.13. View

12.

Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller D . The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2014; 20(24):6504-16. PMC: 4268357. DOI: 10.1158/1078-0432.CCR-14-1553. View

13.

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S . The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23(6):1019-28. DOI: 10.1038/leu.2008.397. View

14.

Jagani Z, Mora-Blanco E, Sansam C, McKenna E, Wilson B, Chen D . Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010; 16(12):1429-33. PMC: 3859448. DOI: 10.1038/nm.2251. View

15.

Zhao D, Zhang M, Huang S, Liu Q, Zhu S, Li Y . CHD6 promotes broad nucleosome eviction for transcriptional activation in prostate cancer cells. Nucleic Acids Res. 2022; 50(21):12186-12201. PMC: 9757051. DOI: 10.1093/nar/gkac1090. View

16.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

17.

Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J . Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017; 542(7642):484-488. PMC: 5448706. DOI: 10.1038/nature21357. View

18.

Ayala R, Willhoft O, Aramayo R, Wilkinson M, McCormack E, Ocloo L . Structure and regulation of the human INO80-nucleosome complex. Nature. 2018; 556(7701):391-395. PMC: 5937682. DOI: 10.1038/s41586-018-0021-6. View

19.

Stanley F, Moore S, Goodarzi A . CHD chromatin remodelling enzymes and the DNA damage response. Mutat Res. 2013; 750(1-2):31-44. DOI: 10.1016/j.mrfmmm.2013.07.008. View

20.

Barisic D, Stadler M, Iurlaro M, Schubeler D . Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature. 2019; 569(7754):136-140. PMC: 6522387. DOI: 10.1038/s41586-019-1115-5. View